Dual functional nanoplatforms potentiate osteosarcoma immunotherapy via microenvironment modulation

Shunyi Lu1,2, Yuqi Yang2, Zhuorun Song1,2

  • 1Department of Orthopedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215123, China.

National Science Review
|February 12, 2025
PubMed

Insights

This study reveals that impaired autophagy in osteosarcoma (OS) can be therapeutically targeted. A novel manganese sulfide nanoplatform (MnSx) reactivates autophagy and enhances anti-tumor immunity for effective osteosarcoma treatment.

Area of Science:

  • Biomedical Engineering
  • Oncology
  • Immunology

Background:

  • Osteosarcoma (OS) is an aggressive bone tumor with limited treatment options.
  • Cellular autophagy is impaired in OS, hindering effective therapeutic strategies.
  • Mitochondrial autophagy inhibition is a key feature observed at the transcriptomic level in OS.

Purpose of the Study:

  • To investigate the therapeutic potential of a dual-functional metal nanoplatform (MnSx) for osteosarcoma (OS).
  • To explore MnSx's ability to shift autophagy from a protective role to a tumor-killing effect in OS.
  • To evaluate MnSx's efficacy in combination with immune checkpoint inhibitors for complete OS remission.

Main Methods:

  • Bioinformatic analysis of clinical OS samples to identify impaired autophagy.
  • Transcriptomic analysis to validate mitochondrial autophagy inhibition in OS.
  • In vitro and in vivo studies using MnSx nanoplatform for therapeutic intervention.

Main Results:

  • MnSx facilitates intracellular H2S generation, promoting mitochondrial autophagy via USP8 S-sulfhydration.
  • MnSx activates the cGAS-STING pathway, enhancing autophagy and tumor cell death.
  • In vivo, MnSx activates autophagy, matures dendritic cells, and activates cytotoxic T lymphocytes, leading to tumor eradication.

Conclusions:

  • MnSx shows potential as a dual-functional therapeutic platform for osteosarcoma.
  • Targeting autophagy via MnSx offers a novel strategy for OS treatment.
  • Combination therapy with immune checkpoint inhibitors holds promise for complete OS remission.

Related Concept Videos